Henri Termeer, the CEO of Genzyme, told the Wall Street Journal's Health Blog last week that he was considering selling some of the company's non-essential business, and this week the company said which ones were for sale: its genetic testing, diagnostics, and pharmaceutical intermediates businesses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.